CNTX
$2.86
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.
Recent News
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data
Context Therapeutics (NASDAQ:CNTX) is focused on developing T-cell engager (TCE) therapies for solid tumors, with an emphasis on addressing resistance that can emerge after antibody-drug conjugate (ADC) treatment, company Chief Executive Officer Martin Lehr said during a fireside chat at Leerink Par
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference
Context Therapeutics (NASDAQ:CNTX) CEO Martin Lehr outlined the company’s strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology company as a developer of T-cell engager (TCE) antibodies for solid tumors. Lehr described TCEs as anti
Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. Indeed, Context Therapeutics...
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...
BioAtla Inc (BCAB) advances strategic transactions and trial designs while navigating financial constraints and operational adjustments.
Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most
Key Insights The considerable ownership by private equity firms in Context Therapeutics indicates that they...